Healthcare provider profile · identity verified

Maryam Qureshi, M.D.

Family Practice · FORSYTH, IL · NPI 1639381817

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	362	101
Levothyroxine Sodium	Levothyroxine Sodium	338	90
Amlodipine Besylate	Amlodipine Besylate	225	70
Losartan Potassium	Losartan Potassium	223	63
Gabapentin	Gabapentin	203	48
Metoprolol Succinate	Metoprolol Succinate	185	51
Omeprazole	Omeprazole	174	54
Lisinopril	Lisinopril	156	41
Rosuvastatin Calcium	Rosuvastatin Calcium	155	43
Montelukast Sodium	Montelukast Sodium	131	40
Hydrochlorothiazide	Hydrochlorothiazide	127	34
Simvastatin	Simvastatin	119	37
Metformin Hcl	Metformin Hcl	117	28
Celecoxib	Celecoxib	109	32
Citalopram Hbr	Citalopram Hydrobromide	107	28
Trazodone Hcl	Trazodone Hcl	98	27
Glipizide Er	Glipizide	91	25
Albuterol Sulfate Hfa	Albuterol Sulfate	89	31
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	86	13
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	80	28
Carvedilol	Carvedilol	79	21
Metoprolol Tartrate	Metoprolol Tartrate	79	21
Tramadol Hcl	Tramadol Hcl	79	29
Glipizide	Glipizide	77	17
Allopurinol	Allopurinol	74	19
Ozempic	Semaglutide	70	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	69	18
Prednisone	Prednisone	64	46
Potassium Chloride	Potassium Chloride	61	14
Furosemide	Furosemide	60	16
Warfarin Sodium	Warfarin Sodium	59	11
Lorazepam	Lorazepam	58	17
Metformin Hcl Er	Metformin Hcl	58	15
Alprazolam	Alprazolam	53	17
Duloxetine Hcl	Duloxetine Hcl	53	14
Fluticasone Propionate	Fluticasone Propionate	53	23
Januvia	Sitagliptin Phosphate	53	suppressed
Clonazepam	Clonazepam	52	suppressed
Tizanidine Hcl	Tizanidine Hcl	52	24
Azithromycin	Azithromycin	49	41
Tamsulosin Hcl	Tamsulosin Hcl	48	15
Clopidogrel	Clopidogrel Bisulfate	46	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	46	15
Ropinirole Hcl	Ropinirole Hcl	45	13
Eliquis	Apixaban	39	suppressed
Trulicity	Dulaglutide	37	suppressed
Buspirone Hcl	Buspirone Hcl	35	12
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	33	suppressed
Paroxetine Hcl	Paroxetine Hcl	33	suppressed
Sertraline Hcl	Sertraline Hcl	33	suppressed
Atenolol	Atenolol	32	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	31	suppressed
Xarelto	Rivaroxaban	31	suppressed
Alendronate Sodium	Alendronate Sodium	30	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	30	suppressed
Meclizine Hcl	Meclizine Hcl	30	12
Spironolactone	Spironolactone	30	suppressed
Hydralazine Hcl	Hydralazine Hcl	28	suppressed
Pravastatin Sodium	Pravastatin Sodium	28	11
Lovastatin	Lovastatin	27	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Farxiga	Dapagliflozin Propanediol	26	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	25	suppressed
Donepezil Hcl	Donepezil Hcl	24	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Meloxicam	Meloxicam	24	15
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	24	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	23	13
Synthroid	Levothyroxine Sodium	23	suppressed
Bupropion Hcl Sr	Bupropion Hcl	22	suppressed
Cephalexin	Cephalexin	22	15
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	21	suppressed
Glimepiride	Glimepiride	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Fenofibrate	Fenofibrate	19	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	19	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	18	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Humalog Kwikpen U-100	Insulin Lispro	18	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Nabumetone	Nabumetone	18	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	14
Bupropion Xl	Bupropion Hcl	16	suppressed
Clonidine Hcl	Clonidine Hcl	15	suppressed
Olanzapine	Olanzapine	15	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	13
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	13
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	14	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	suppressed
Dilt-Xr	Diltiazem Hcl	13	suppressed
Enalapril Maleate	Enalapril Maleate	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	13	suppressed
Midodrine Hcl	Midodrine Hcl	13	suppressed
Ondansetron Odt	Ondansetron	13	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	13	suppressed
Topiramate	Topiramate	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Folic Acid	Folic Acid	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	12	suppressed
Latanoprost	Latanoprost	12	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	11
Repatha Syringe	Evolocumab	12	suppressed
Trueplus Pen Needle	Pen Needle, Diabetic	12	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	11	suppressed
Fosinopril Sodium	Fosinopril Sodium	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Nystatin	Nystatin	11	suppressed
Pregabalin	Pregabalin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error